T he first step in insulin action involves binding to a specific high-affinity receptor on the cell surface. The human insulin receptor is an intergral membrane glycoprotein (M r ~ 350,000-400,000) that is composed of two a-subunits (M r ~ 125,000-135,000) and two p-subunits (M r ~ 90,000), held together by disulfide bonding. 13 The insulin receptor possesses tyrosine-specific protein kinase activity that is activated by binding of insulin to the receptor. 4 -7 Activation of the tyrosine-specific protein kinase activity very likely represents a key mechanism for transmembrane signaling by the hormone. Recently Ullrich et al. 8 have isolated and sequenced a complementary DNA (cDNA) clone for the human placental insulin receptor gene. Metabolic labeling and affinity labeling studies, 911 and the amino acid sequence deduced from the nucleotide sequence of the cDNA, 8 have indicated that the a-and p-chains are synthesized as a single high-molecular-weight precursor polypeptide with the a-chain at the amino end and the (3-chain at the carboxyl end. Based on the DNA sequence, the predicted molecular weight of the unglycosylated a-chain is 82,400 and the (3-chain is 69.700.
- 7 Activation of the tyrosine-specific protein kinase activity very likely represents a key mechanism for transmembrane signaling by the hormone. Recently Ullrich et al. 8 have isolated and sequenced a complementary DNA (cDNA) clone for the human placental insulin receptor gene. Metabolic labeling and affinity labeling studies, 911 and the amino acid sequence deduced from the nucleotide sequence of the cDNA, 8 have indicated that the a-and p-chains are synthesized as a single high-molecular-weight precursor polypeptide with the a-chain at the amino end and the (3-chain at the carboxyl end. Based on the DNA sequence, the predicted molecular weight of the unglycosylated a-chain is 82,400 and the (3-chain is 69.700. 8 The p-chain contains a transmembrane domain and a cytoplasmic protein kinase domain that has sequence homology with other tyrosine-specific protein kinases, including the epidermal growth factor (EGF) receptor, and a number of retroviral oncogenes including the y-src oncogene of Rous sarcoma virus and the v-ras oncogene of avian sarcoma virus UR2. 8 Evidence suggests that the insulin binding site resides primarily on the external a-subunit domain. 18 Insulin resistance at the tissue level is important in the etiology of type II (non-insulin-dependent) diabetes mellitus 12 as well as a number of rare syndromes including lipoatrophic diabetes, leprechaunism, and syndromes of insulin resistance and acanthosis nigricans (reviewed in refs. 13 and 14) . A decrease in insulin receptor numbers or a qualitative change in insulin receptors has been demonstrated in a number of these disorders. In some of these disorders the deficiency of insulin receptors is clearly a secondary consequence of other metabolic problems. For example, in type B syndrome of insulin resistance and acanthosis nigricans, the decrease in insulin receptor numbers and insulin resistance are caused by circulating autoantibodies directed against the insulin receptor. 13 However, evidence suggesting an intrinsic defect in the insulin receptor has been obtained for two other rare syndromes, leprechaunism and type A syndrome of insulin resistance and acanthosis nigricans. Qualitative or quantitative defects in insulin receptors have been found in fibroblasts or lymphocytes cultured from three patients with leprechaunism accompanied by extreme insulin resistance (reviewed in ref. 14) . Insulin resistance has also been observed to be correlated with a defect in insulin receptors on fibroblasts or lymphocytes cultured from several patients with type A syndrome of insulin resistance and acanthosis nigricans. 15 " 19 In one of these cases a family study strongly suggested a genetic basis for the deficiency in insulin receptors. 17 It would be of considerable interest to determine whether any of these disorders is caused by a mutation in the insulin receptor gene or its controlling elements.
Southern blot analysis suggests that there is a single copy of the insulin receptor gene per haploid chromosome set, 8 and very recently, Yang-Feng et al. 20 have used recombinant DNA methods to provisionally assign the receptor gene to human chromosome 19. We report here data obtained by a different method that supports assignment of the receptor gene to chromosome 19.
MATERIALS AND METHODS
Isolation of hybrid clones. Hybrid clones were isolated by crossing diploid human skin fibroblasts with two derivatives of the mouse L cell line: A9, which contains a mutation in the gene for hypoxanthine-guanine phosphoribosyl transferase (HPRT) and B82, which contains a mutation in the gene for thymidine kinase (TK). 21 Hybrid clones (Table 1) were selected in HAT medium 21 and karyotyped by the fluorescence banding procedure as described previously. 22 Strain GM969 normal diploid human skin fibroblasts were obtained from the Human Genetic Mutant Cell Repository, Camden, New Jersey. Cell culture and preparation of crude membrane fractions. Hybrid cells were grown to confluence in 10-15 10-cm dishes containing minimal essential medium (MEM) supplemented with 0.1 mM nonessential amino acids, 10% fetal bovine serum (Gibco, Grand Island, New York), penicillin (71 U/ml), streptomycin (100 |xg/ml), and HAT. 21 The human fibroblasts, A9 cells, and B82 cells were grown in the same medium minus HAT. For preparation of crude membrane fractions, cells were placed on ice, washed twice with phosphate-buffered saline (PBS), and removed from the dishes by scraping. All subsequent operations were performed at 4°C. Cells were recovered by centrifugation, resuspended in 10 ml of hypotonic buffer [8.5 mM tris-HCI, 3.0 mM NaCI, 1.0 mM glucose, 0.2 mM MgCI 2 , 0.1 mg/ml bovine serum albumin, 10mM benzamidine-HCI, 10|i.g/ml phenylmethyl sulfonylfluoride (PMSF), pH 7.8], and allowed to swell for 10 min. The cells were then homogenized with a Dounce homogenizer, and the homogenate was centrifuged for 10 min at 581 x g. The pellet was discarded and the supernatant was centrifuged for 1 h at 50,000 x g. Pellets from the high-speed spin were stored frozen at -70°C before use. Membrane solubilization. Membrane pellets were thawed, suspended in 250 (xl of solubilization buffer (50 mM tris-HCI + 1 mM Triton X-100, pH 7.5), and incubated at 23°C for 15 min with frequent agitation. The solubilized membranes were then centrifuged in an airfuge at 30 psi (149,000 x g) for 20 min to remove insoluble particulate material. The clear supematants were assayed for the presence of human insulin receptors as described below. Protein in the solubilized membrane fractions was measured by the method of Lowry et al. 23 , as modified by Wang and Smith. Porcine insulin (Elanco, Indianapolis, Indiana) was iodinated by the stoichiometric method to a specific activity of approximately 150 ixCiVg, as previously described. 24 Solubilized membrane preparations (40-150 |xg protein) were incubated with 125 l-insulin (50,000 or 500,000 cpm) in assay buffer (50 mM tris-HCI, 0.1% bovine serum albumin, 70 U/ml bacitracin, pH 7.7) in a 200-^1 total volume, in the absence or presence of 2 \LQ of unlabeled insulin. Parallel controls were also performed in which membrane protein was omitted. A 20-JJLI aliquot of a 1/40 dilution of alR-1 2526 clarified ascites in 50-fold diluted normal mouse serum was then added, and incubation was continued at 4°C for 6 h. Parallel controls were performed using a class-matched 7GI (kappa) subclass ascites (MOPC 21). At the end of the 6-h incubation, 20 |xl of a 1/3 dilution of goat anti-mouse antiserum was added, and incubation was continued for 16 h at 4°C. Assay buffer (1 ml, 4°C) was added to each tube, and precipitates were collected by centrifugation in a microfuge (8730 x g) for 10 min at 4°C. Supematants were removed, and radioactivity in the pellet was determined with a Beckman Biogamma-2 gamma counter (efficiency 78%) (Beckman Instruments, Fullerton, California).
RESULTS AND DISCUSSION
In this study we used the alR-1 anti-human insulin receptor monoclonal antibody 2526 to detect insulin receptors in solubilized membrane preparations. This antibody offered two distinct advantages for this study. First, it exhibits very little, if any, cross-reactivity with rodent insulin receptors 25 and can thus be used to detect human insulin receptors on the surface of human x rodent hybrid cells. Second, the odR-1 antibody exhibits a relatively high degree of specificity for the insulin receptor. 26 The insulin-like growth factor I (IGF-I) receptor has a subunit structure that is homologous to the insulin receptor, and IGF-I receptors bind insulin with a low affinity. 2728 Furthermore, indirect evidence suggests that the insulin and IGF-I receptors may share some immunologic determinants. 29 However, because of the high affinity of binding of insulin to its own receptor and the specificity of the alR-l antibody for the insulin receptor, immunoprecipitation assays performed with 125 l-insulin as ligand and the alR-1 antibody detect primarily or exclusively insulin receptors. 26 In initial experiments (Table 2) , solubilized membrane preparations were incubated in the presence of 50,000 cpm (0.2 ng) of 125 l-insulin, and the 125 l-insulin-receptor complexes were immunoprecipitated. Controls included (1) parallel assays performed in the presence of a high concentration of competing unlabeled insulin, (2) parallel assays in which insulin-receptor complexes were mock precipitated with a class-matched control monoclonal antibody (MOPC 21) not directed against the insulin receptor, and (3) control assays in which the receptor was omitted. Cells were scored as positive for the human insulin receptor if the amount of ra- (Table 2) . Two human fibroblast x L cell hybrids containing different complements of human chromosomes were also assayed for human insulin receptors by this method ( Table 2) . Hybrid clone CF67-7 was scored as a clear positive in this assay, while hybrid clone CF31-1 was scored as a clear negative.
We found subsequently that the sensitivity of the assay could be improved by using 500,000 cpm rather than 50,000 cpm of 125 l-insulin in the assay. Five human fibroblast x L cell hybrid clones were assayed for human insulin receptors by the improved method (Table 3) . Two of the hybrids, CF67-7 and CF33-16, yielded a positive result, while three others, CF31-1, CF67-2, and CF80-8, yielded negative results. An examination of the karyotypes of the five hybrids (Table 1) indicates that human chromosome 19 is the only possible chromosomal assignment for the insulin receptor gene.
Yang-Feng et al. 20 have recently used a cDNA probe 8 to provisionally assign the human insulin receptor gene to the short arm of chromosome 19. The possibility that the probe used in their study was actually derived from the IGF-I receptor gene has not been conclusively ruled out. The present results, obtained by a different approach, support the assignment of the insulin receptor gene to chromosome 19. Further genetic studies will be required to establish DIABETES, VOL. 34, AUGUST 1985 IUMAN INSULIN RECEPTOR GENE whether any of the human syndromes characterized by insulin resistance are caused by mutations in the insulin receptor gene or its controlling elements. Interestingly, myotonia dystrophica has been mapped by linkage analysis to the short arm of chromosome 19. 30 Myotonia dystrophica is characterized by insulin resistance, and a study of 12 patients with myotonia dystrophica indicated a reduction of insulin binding to circulating mononuclear blood cells. 31 It would be of considerable interest to determine whether the gene for myotonia dystrophica and the gene for the insulin receptor are genetically linked.
